With a market cap of $18.4 billion, Insulet Corporation (PODD) is a leading developer of innovative insulin delivery systems ...

Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This ...

The stock's rise snapped a four-day losing streak.

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient ...

Data from a controlled trial indicates that patients who switched from daily insulin injections to its Omnipod 5 automated ...

Envestnet Portfolio Solutions Inc. increased its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 2.3% during ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Just shy of two years after a C-suite reorganization at Insulet, Mark Field has left his position as the inaugural chief ...

Corporation shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled ...

Participants began with an average HbA1c level of 8.1%. After three months, people who used Omnipod 5 improved HbA1c by an ...

Independent Advisor Alliance grew its position in Insulet Co. (NASDAQ:PODD – Free Report) by 20.8% in the 4th quarter, ...